Clinical Trial Update: Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk

View source ↗

Summary

Clinical trial update evaluating ProALL microRNAs in blood to predict relapse risk in B-cell acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Snippet

Sponsor: Curewize Health Ltd. | Conditions: B-cell Acute Lymphoblastic Leukemia | Status: UNKNOWN